King's Research Portal

DOI:

[10.1017/S0029665117000428](https://doi.org/10.1017/S0029665117000428)

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Hall, W. L. (2017). The future for long chain n-3 PUFA in the prevention of coronary heart disease: do we need to target non-fish-eaters? *Proceedings of the Nutrition Society*, 1-11.

<https://doi.org/10.1017/S0029665117000428>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Conference on 'New technology in nutrition research and practice' Silver Medal Lecture

The future for long chain *n*-3 PUFA in the prevention of coronary heart disease: do we need to target non-fish-eaters?

W. L. Hall

Diabetes and Nutritional Sciences Division, Faculty of Life Sciences and Medicine, King's College London,
London, UK

Dietary guidelines in many countries include a recommendation to consume oily fish, mainly on the basis of evidence from prospective cohort studies that fish consumption is cardioprotective. However, average intakes are very low in a large proportion of the UK population. Some groups, such as vegans and vegetarians, purposely omit fish (along with meat) from their diet resulting in zero or trace intakes of long chain (LC) *n*-3 PUFA. Although the efficacy of dietary fish oil supplementation in the prevention of CVD has been questioned in recent years, the balance of evidence indicates that LC *n*-3 PUFA exert systemic pleiotropic effects through their influence on gene expression, cell signalling, membrane fluidity and by conversion to specialised proresolving mediators; autacoid lipid mediators that resolve inflammatory events. The long-term impact of reduced tissue LC *n*-3 PUFA content on cardiovascular health is surprisingly poorly understood, particularly with regard to how low proportions of LC *n*-3 PUFA in cell membranes may affect cardiac electrophysiology and chronic inflammation. Randomised controlled trials investigating effects of supplementation on prevention of CHD in populations with low basal LC *n*-3 PUFA tissue status are lacking, and so the clinical benefits of supplementing non-fish-eating groups with vegetarian sources of LC *n*-3 PUFA remain to be determined. Refocusing dietary LC *n*-3 PUFA intervention studies towards those individuals with a low LC *n*-3 PUFA tissue status may go some way towards reconciling results from randomised controlled trials with the epidemiological evidence.

n-3 PUFA: CHD: Heart rate variability: Inflammation: Lipid mediators

Seafood has been a key component of human diets for thousands of years, and is rich in long chain (LC) *n*-3 PUFA, EPA (20 : 5*n*-3) and DHA (22 : 6*n*-3). Endogenous synthesis of EPA can occur in the human body to a limited extent when there is a dietary supply of the shorter chain, plant-derived *n*-3 PUFA, α -linolenic acid (ALA, 18 : 3*n*-3), but further conversion to DHA appears to occur only on a very small scale⁽¹⁾. Microscopic, single-celled marine organisms carry out *de novo* synthesis of LC *n*-3 PUFA resulting in concentrated amounts of EPA and DHA in the seafood that is commonly consumed by human subjects further up the marine food chain. In fact, the role of microalgae as primary producers of EPA and DHA may have

been a key driver that enabled the evolutionary adaptation response of early *Homo sapiens* to environmental pressures. A plausible theory posits that an increased reliance on marine resources by early human subjects began in Africa about 140 000 years ago and allowed the modern human brain to grow rapidly due to a ready supply of dietary DHA^(2–4). DHA comprises approximately 40 % of total PUFA in the mammalian central nervous system⁽⁴⁾ and proponents of the marine/brain theory postulate that rapid encephalisation and increasing neural plasticity opened the way to behavioural innovations that enabled population expansion along the African coast and beyond⁽⁵⁾.

Abbreviations: ALA, α -linolenic acid; HR, heart rate; HRV, heart rate variability; LA, linoleic acid; LC, long chain; SPM, specialised pro-resolving mediators.

Corresponding author: Dr W. L. Hall, email wendy.hall@kcl.ac.uk

An adequate supply of LC *n*-3 PUFA is vital for development and maintenance of the nervous system, a topic that has been comprehensively reviewed elsewhere^(6–9). A functioning central and peripheral nervous system, particularly the autonomic nervous system comprising sympathetic and parasympathetic nerves, is also essential for cardiovascular health, including homeostasis of blood pressure and heart rate (HR) by innervation of blood vessels and the pacemaker respectively. Marine LC *n*-3 fatty acids profoundly influence cardiovascular function (HR, blood pressure), by influencing neuronal function in the hypothalamus, sympathetic and parasympathetic neurons and the intrinsic cardiac nervous system by neurotrophic and neuroprotective mechanisms⁽¹⁰⁾, including anti-inflammatory mechanisms^(11,12). Accumulated evidence to date suggests that dietary fish consumption is protective against cardiac mortality⁽¹³⁾ and the potentially anti-arrhythmic effects of LC *n*-3 PUFA at relatively low doses are likely to be a significant contributor to these observed effects^(14,15).

Organisations with the authority to set dietary guidelines across the world are in agreement that inclusion of fish in the diet, particularly oily fish, or supplemental fatty acids derived from fish, is likely to be protective against CVD⁽¹⁶⁾. The link between marine fatty acids and CVD has been intensively investigated since the earliest reports appeared in the latter half of the last century of associations between high LC *n*-3 PUFA intakes and low rates of CVD in Canadian and Greenland Inuits^(17–19). Epidemiological studies support the theory that fish consumption reduces the risk of CHD mortality^(13,20) and meta-analyses of studies measuring blood or tissue levels of EPA + DHA at baseline have shown inverse associations with risk of coronary events⁽²¹⁾. The lack of effect in more recent primary and secondary prevention randomised controlled trials of fish oil supplementation⁽²²⁾, in contrast to earlier well-known trials^(15,23,24) has been debated at length^(25–28). Factors such as reduced bioavailability of supplemental oils if consumed with low-fat meals or no food at all, concomitant medications obscuring therapeutic benefit (e.g. statins) and the amount of EPA and DHA already present in the body tissues, may have been critical determinants of clinical efficacy. A critical question is whether individuals with a risk profile indicating increased cardiovascular risk due to a low EPA and DHA tissue status, might benefit more from dietary LC *n*-3 PUFA supplementation than those whose tissue fatty acid profile is relatively enriched with EPA and DHA. Only 23 % of UK adults aged 19–64 report consuming oily fish and if this is accurate, it presents the possibility that a large proportion of the UK population may have sub-optimal concentrations of LC *n*-3 PUFA in their tissues and may be at increased risk of CHD mortality⁽¹³⁾. Dietary intakes of fish and fish oil fatty acids vary widely for a variety of reasons, including lifestyle choices, for example vegetarianism, access to food/food security, food preferences and religious dietary restrictions. Furthermore, individual dietary requirements for fish oil fatty acids are likely to vary due to genetic variation (for example polymorphisms in the desaturase and elongase genes^(29–31)) and possibly background inflammatory burden, which may also be partly

genetically determined⁽³²⁾. The aim of this review is to examine what we know about the consequence of low dietary EPA and DHA intakes and to consider what the cardiovascular health impact might be in otherwise healthy populations.

ω-3 Index and cardiovascular health

A widely accepted method to assess an individual's medium-term dietary intakes of LC *n*-3 PUFA, is by measuring the percentage of erythrocyte membrane fatty acids (erythrocyte phospholipids) that are EPA and DHA, which correlates closely with the EPA + DHA content in cardiac tissue⁽³³⁾. Proportions of EPA + DHA in erythrocyte phospholipids have been identified as an independent predictor of CVD risk^(34,35). Erythrocyte EPA + DHA as a % of total erythrocyte fatty acids is termed the ω-3 index, with ≥8 % considered to be associated with the maximum protective effect⁽³⁴⁾. Incorporation of supplemented EPA + DHA into erythrocyte membranes occurs in a dose-response fashion and significant increases can be measured over a supplementation period of 2–12 months at relatively low doses akin to intake of 1–4 portions of oily fish per week⁽³⁶⁾. The effects of age and sex on the efficiency of incorporation of supplemental EPA and DHA in blood cells and plasma fractions seem to be relatively minor⁽³⁷⁾, but there may be an increased efficiency of uptake in individuals with lower baseline intakes of LC *n*-3 PUFA⁽³⁸⁾ and potentially at times of greater need such as during pregnancy⁽³⁹⁾. Reported average ω-3 indices vary widely in human populations that are identified as being omnivorous, most likely representing the fact that meat-consumers who eat very little fish will have much lower proportions of EPA and DHA in their membrane lipids than meat-consumers who also regularly consume fish, whereas reported ω-3 indices in vegans are distinctly lower compared with meat and fish-eaters (Table 1). Observational evidence suggests that low whole blood or erythrocyte membrane levels of EPA and DHA are associated with a greater risk of sudden cardiac death, primary cardiac arrest, acute coronary syndrome^(14,40,41) and a meta-analysis of prospective cohort studies that measured circulating fatty acids showed associations between higher EPA and DHA and lower relative risks of coronary outcomes⁽²¹⁾.

Cardiovascular health of populations with low ω-3 index: vegetarians and vegans

Evidence from prospective cohort studies with a high proportion of vegetarians and vegans suggests that they are less likely to develop CHD than meat- and fish-consumers. For example, a 1999 meta-analysis of five prospective studies (USA, UK, Germany) reported that vegetarians had 24 % lower mortality from CHD (specific to those who followed diet for >5 years)⁽⁴²⁾. Additional prospective cohorts included in more recent meta-analyses agreed with earlier findings^(43,44). Reduced risk of CHD appears to be

Table 1. Erythrocyte EPA and DHA (% or absolute concentrations) of meat- and fish-consumers (omnivores), vegetarians and vegans

Reference	Omnivore	Vegetarian*	Vegan
Wt%			
Cottin <i>et al.</i> ⁽¹²⁷⁾	6.8	–	–
Geppert <i>et al.</i> ^{(118)*}	–	4.7	–
Johnston <i>et al.</i> ⁽¹²⁸⁾	3.5	–	–
Pinto <i>et al.</i> ⁽⁸⁰⁾	5.4	–	2.7
Reidlinger <i>et al.</i> ⁽¹²⁹⁾	7.1	–	–
Sanders <i>et al.</i> ⁽¹³⁰⁾	8.5	–	–
Sanders <i>et al.</i> ⁽¹³¹⁾	7.5	–	–
Sarter <i>et al.</i> ⁽¹¹⁵⁾	–	–	3.7
Mol%			
Agren <i>et al.</i> ⁽¹³²⁾	8.1	–	3.5
Fokkema <i>et al.</i> ⁽¹³³⁾	4.5	–	2.3
Kornsteiner <i>et al.</i> ⁽¹¹⁰⁾ (erythrocyte sphingo- and phospholipids)	2.2	1.6	1.0
Rajaram <i>et al.</i> ⁽¹³⁴⁾	5.0	–	–
Absolute concentrations			
Sanders <i>et al.</i> ⁽¹³⁵⁾ (mg/g total methyl esters)	66	–	20

Wt%, weight percentage of the sum of fatty acids; mol%, mole percentage of the sum of fatty acids.

* A vegetarian was defined as someone who ate no meat and not more than one fish meal a month.

driven by lower blood LDL cholesterol, blood pressure and possibly lower BMI in vegans/vegetarians^(45–47). Taking this evidence at face value it appears that a vegetarian/vegan diet may be a cardio-protective diet. It has been suggested that there seems to be a minimum basal rate of conversion of ALA to DHA, which is sufficient to maintain cardiovascular health where dietary sources of pre-formed LC *n*-3 PUFA are lacking^(48,49). Furthermore, authors of an observational study, using statistical estimates of ALA to longer chain *n*-3 PUFA conversion rates, suggested that conversion might actually be increased in non-fish eaters compared with fish-eaters. This would account for the relatively low margin of difference in ω -3 indices of fish-eaters compared with non-fish eaters⁽⁵⁰⁾, although conversion rates to DHA specifically were not clear.

Closer inspection of the observational evidence for coronary risk in vegetarians/vegans, raises the question of whether it is valid to translate these findings to the wider population. Vegetarian/vegan cohorts vary in their motivations for dietary choice (religious, health, animal welfare), which may converge with other distinct lifestyle behaviours that may affect cardiovascular health (physical exercise, practising mindfulness/meditation/prayer, prevalence of alcohol and drug use). This concern seems particularly pertinent to the Seventh Day Adventist cohorts. Kwok *et al.* applied sub-group testing in their meta-analysis of seven prospective cohort studies that evaluated mortality and clinical cardiovascular outcomes in vegetarian populations compared with non-vegetarian controls and revealed that the overall pooled difference in risk of cardiac events was mainly driven by the Seventh Day Adventist cohorts⁽⁴⁴⁾, suggesting that the results from this particular population might not be generalisable to other populations. Furthermore, the

definition of vegetarian in Seventh Day Adventist cohorts tends to be inconsistent with the generally accepted definition of eating no meat or fish. Seventh Day Adventist cohorts incorporated into the pooled analyses^(42,44) included those who ate meat <1/week or less with no mention of what their fish intakes were^(51,52), or were otherwise not clearly defined⁽⁵³⁾. It is therefore possible that the Adventist cohorts were also fish-consumers and may have had higher ω -3 indices than 'true' vegetarians/vegans who do not eat any fish. The more recent Adventist Health Study 2 clearly defined participants as vegans, lacto-ovo vegetarians, pesco-vegetarians, semi-vegetarians and non-vegetarians⁽⁵⁴⁾. The results of Adventist Health Study 2 showed that the reduced risk in CHD mortality was not quite statistically significant (hazard ratio 0.81, 95% CI 0.64, 1.02) for all vegetarians combined. Further analysis of dietary sub-groups revealed that the reduced risk was significant in pesco-vegetarians when both sexes were combined (hazard ratio 0.65, 95% CI 0.43, 0.97) but not vegans (hazard ratio 0.90, 95% CI 0.60, 1.33) or lacto-ovo vegetarians (hazard ratio 0.90, 95% CI 0.76, 1.06).

The UK vegetarian/vegan cohorts might be considered more generalisable to the broader population since they are not affiliated with a religious faith and may be more diverse in terms of demographics and lifestyle behaviours. Furthermore, vegetarians and vegans were clearly defined as not eating meat or fish^(47,55,56) and the vegetarian and vegan men from the EPIC-Oxford cohort were reported to have lower EPA and DHA proportions of total plasma fatty acids compared with omnivores, providing an objective biomarker of low fish intake⁽⁵⁷⁾. Although vegetarians/vegans had a lower incidence of CHD in the UK EPIC-Oxford cohort⁽⁵⁶⁾, there was no difference in CHD mortality compared with controls who ate meat and fish (death rate ratio 0.83, 95% CI 0.59, 1.18)⁽⁵⁸⁾. The latter study may have been statistically underpowered, but a more recent combined analysis of mortality rates (total 644 CHD deaths) reported that there was no significant difference in CHD mortality in UK vegans/vegetarians up to 90 year (nor 75 year) compared with comparable regular meat-eaters (hazard ratio 0.99, 95% CI 0.79, 1.23)⁽⁵⁵⁾, who consumed meat $\geq$ 5 times/week as well as fish.

In translating these observations to the question of the cardiovascular health impact of low EPA + DHA tissue status, it is impossible to cleanly dissect the influence of dietary LC *n*-3 fatty acid intake from other dietary influences. For example, vegetarian/vegan diets are lower in SFA, higher in fibre, but can also be deficient in bio-available iron, vitamin B₁₂ and vitamin D. Low serum 25-hydroxyvitamin D concentrations are also associated with increased CVD mortality⁽⁵⁹⁾. Furthermore, the nature of the comparator group is an important consideration, particularly as health-conscious participants were recruited to UK cohorts who tended to have lower intakes of dietary animal protein compared with Adventist non-vegetarian/non-vegans⁽⁵⁶⁾. However, equivalent CHD mortality rates could alternatively signify that the vegetarian/vegan diet is also associated with other raised CHD risk factors (e.g. low ω -3 index) that might negate the otherwise cardio-protective effects of a vegetarian/vegan

Fig. 1. Theoretical schematic showing how low long chain *n*-3 PUFA intakes may oppose the cardioprotective effects of vegetarian/vegan diets, resulting in an equivalent risk of CHD mortality (A). The majority of the UK population eats little or no fish and may be at risk of low ω -3 status. Without the counterbalancing cardio-protective qualities of a vegetarian/vegan diet, this could lead to an increased risk of CHD mortality mediated by arrhythmia (B). Picture of artery attributed to 'Blausen gallery 2014'⁽¹³⁶⁾.

diet. It is hypothesised here that long-term low tissue LC *n*-3 PUFA levels may counterbalance the athero-protective qualities of vegetarian/vegan diets in the sum effect on overall CHD mortality risk. The implications of this for the sizeable non-fish-eating, non-vegetarian/non-vegan population are more serious. Low tissue EPA and DHA levels in a less health-conscious meat-eating population might have a more deleterious effect on cardiovascular health, such as increasing risk of cardiac arrhythmia, against the background of higher LDL-cholesterol, blood pressure and BMI. Fig. 1 summarises the counterbalance of dietary factors that may positively or negatively influence risk of CHD mortality in non-fish eaters. The next sections will address the cardiovascular risk factors that may mediate increased risk of CHD mortality in populations with very low LC *n*-3 PUFA intakes, including low HR variability (HRV) and a reduced capacity to regulate inflammatory responses.

Heart rate variability and risk of arrhythmia

Low HRV indicates a reduced capacity to regulate HR in response to internal and external stressors and demands, and is associated with mortality after a myocardial infarction^(60–62) and risk of cardiac events in the general population⁽⁶³⁾. Low HRV is considered to be a predictor of sudden cardiac death⁽⁶⁴⁾. Therefore, measurement of parameters of short- and long-term variability in heart beat intervals (RR intervals, or interbeat intervals) using Holter monitors or less intrusive HRV/accelerometry integrated chest-worn monitors (e.g. Actiheart, eMotion Faros), can be a useful non-invasive method to assess the adaptability/resilience of the heart. HRV is partly under the control of the autonomic nervous system, which receives afferent impulses from, and exerts efferent activity to, the intrinsic cardiac nervous system, which interacts with the sino-atrial node. Consequently,

variability in HR reflects the sum effect of sympathetic and parasympathetic outflow. Low HRV is associated with a high degree of sympathetic activity (which raises HR thus reducing the capacity to self-regulate in response to demand) and suppressed parasympathetic activity (vagal activity slows HR). Higher LC *n*-3 PUFA tissue status or fish consumption has been positively associated with HRV^(65,66). Mixed results have been obtained in previous investigations into the effect of *n*-3 PUFA on HRV in healthy subjects^(66–69), haemodialysis patients⁽⁷⁰⁾, subjects with previous myocardial infarction^(71–74) and patients with epilepsy⁽⁷⁵⁾. These studies were typically only 12 weeks long, the durations of HR monitoring differed widely and relatively high doses of *n*-3 PUFA ranged from 1 to 6.6 g. Furthermore, comparisons between studies are difficult due to different HRV parameters being reported, varying study designs, and methodological inconsistencies. Nevertheless, fish oil supplementation has been shown to increase a parameter of beat-to-beat (vaguely regulated) HRV in a meta-analysis of randomised controlled trials⁽⁷⁶⁾, supporting the role of adequate tissue EPA + DHA status in preventing arrhythmic events. Thus autonomic balance may be improved by increased EPA and DHA membrane levels, although a direct effect on pacemaker activity independently of the autonomic nervous system may also occur. Increasing LC *n*-3 PUFA content in rabbit cardiomyocyte membranes decreases HR in isolated hearts and reduces pacemaker activity and pacemaker current in sinoatrial node cells^(77,78). In accord with its effects on HRV in clinical trials, fish oil supplementation also reduces HR in human studies⁽⁷⁹⁾.

In summary, fish consumption and to some extent fish oil supplementation, is associated with reductions in HR and increased HRV, which would be predicted to reduce the risk of arrhythmia. However, the impact on HRV of consuming a LC *n*-3 PUFA-free diet was unexplored until recently, when we addressed this question in a cross-sectional study in vegans and age- and BMI-matched

omnivores, measuring the average duration of interbeat intervals (the reciprocal of HR), HRV, erythrocyte phospholipid fatty acids, plasma fatty acids and oxygenated PUFA metabolites⁽⁸⁰⁾. Vegans had lower day-time beat-to-beat HRV and shorter day-time interbeat intervals compared with omnivores, adjusted for age, sex, BMI and physical activity levels by accelerometry. Twenty-four hour HRV was higher in vegans due to the greater night-day differences in vegans compared with omnivores, which was mainly due to the relatively lower HRV during the day rather than higher HRV at night in vegans; no differences between groups during nocturnal sleep were observed. This could indicate a greater predominance of sympathetic regulation (associated with reduced parasympathetic activity) during waking hours due to an exaggerated response to stimuli, or a direct effect of low LC *n*-3 PUFA membrane concentrations in cardiac cells on the pacemaker that manifested in altered cardiac function under conditions of stimulation. There were no differences in serum vitamin D or B₁₂ status between the groups, factors which may also have impacted on HRV. Although these observations only demonstrate an associative link, *n*-3 PUFA tissue status is implicated as a strong candidate for being the key factor in determining the disparate HRV patterns during waking hours observed in vegans and omnivores.

Dampening and resolving inflammation

Both *n*-6 and *n*-3 PUFA in cell membranes can be metabolised into an array of pro- and anti-inflammatory metabolites that are likely to influence prevention of arrhythmia by influencing myocyte cell-signalling and also autonomic function. Chronic inflammation is the key underlying factor in the lifelong accrual of vascular lesions that eventually leads to atherosclerosis and CHD, and LC *n*-3 PUFA supplementation appears to improve plaque stability⁽⁸¹⁾. Although the role of inflammation in initiating and propagating atherosclerosis is at the crux of CHD, chronic inflammation probably also increases coronary risk independently of atherosclerosis by impairing neuronal function⁽⁸²⁾ and myocyte membrane properties⁽⁸³⁾, thereby having a direct influence on cardiac electrophysiology and risk of arrhythmia^(84,85). LC *n*-3 PUFA levels in plasma and erythrocytes are inversely associated with circulating markers of inflammation (C-reactive protein, IL-6, IL-1 receptor antagonist, TNF receptor 2, transforming growth factor- β)⁽⁸⁶⁻⁸⁸⁾. LC *n*-3 PUFA may lower inflammatory burden in a number of ways: by inhibiting the conversion of LA to more pro-inflammatory eicosanoids by substrate competition, being converted themselves to less potent pro-inflammatory eicosanoids, modulation of transcription factor activation, inhibiting the expression of vascular cell adhesion molecules and cytokines, and through the inflammation-resolving properties of their oxygenated metabolites⁽¹¹⁾. The lack of sensitivity of measurements of circulating inflammatory biomarkers, and also the large variability due to hyper-responsivity to short-term infections, has up to now hindered efforts to build a body of evidence for a role of LC

n-3 PUFA in modulating chronic, low-grade inflammation in the context of CVD⁽⁸⁹⁾. The relatively recent detection of a diverse array of oxygenated PUFA metabolites presents a whole new line of investigation with respect to the anti-inflammatory effects of marine fatty acids. Some of the lipid mediators derived from LC *n*-3 PUFA, termed specialised pro-resolving mediators (SPM), act in an autacoid manner to resolve inflammation (Fig. 2). SPM play a functional role in ending acute inflammatory events by inhibition of neutrophil influx to the site of trauma, counter-regulating pro-inflammatory cytokines and stimulating resolving macrophages to clear the products of the inflammatory response, thereby allowing the injured area to heal⁽⁹⁰⁾. Protectin-D1 (originally termed neuroprotectin) is thought to be important in inhibiting proinflammatory gene expression and promoting nerve regeneration in neural tissue, thereby protecting neurons from inflammation-related injury in a DHA-dependent manner^(12,91). DHA-derived neuroprostanes, F₄ isoprostane-like compounds formed non-enzymatically through free radical-catalysed reactions, are also thought to be significant markers of oxidative stress in neural tissue⁽⁹²⁾; furthermore, hepatic F₄-neuroprostanes are negatively associated with the extent of atherosclerotic plaque⁽⁹³⁾, inhibit inflammatory cell signalling in macrophages⁽⁹⁴⁾ and may have cardiac arrhythmic effects⁽⁹⁵⁾.

SPM, namely E- and D- series resolvins (RvD1 and RvE1), the DHA-derived (neuro)protectin-D1 and maresin (MaR1), are released in nano- and pico-molar concentrations at sites of local inflammation, can be detected in *ex vivo* cultured mononuclear cells following EPA + DHA supplementation⁽⁹⁶⁾ and sometimes resolvins can be detected in human plasma although concentrations are not responsive to supplementation⁽⁹⁷⁻¹⁰⁰⁾. Large changes in other postprandial and fasting oxygenated PUFA metabolites have been reported in response to fish oil supplementation^(99,101). But the lipid mediator profiles of unsupplemented populations remain undetermined, particularly those who have very low or zero habitual dietary LC *n*-3 PUFA intakes. We investigated whether the vegans in our cross-sectional study also had lower circulating concentrations of oxygenated EPA and DHA metabolites, since this might have implications for their ability to resolve acute and chronic inflammation. It was observed that vegans had significantly lower plasma concentrations of EPA- and DHA-derived lipid mediators compared with omnivores, including 18-HEPE, 17-HDHA and 14-HDHA, likely precursor markers for RvE1, RvD1 and MaR1 availability, respectively⁽⁸⁰⁾. Although circulating plasma concentrations of lipid mediators are likely to be an insensitive marker of capacity for autacoid release and activity of SPM in specific inflamed sites in the nervous and cardiovascular systems, higher concentrations of precursor markers of SPM bioavailability (18-HEPE, 17-HDHA and 14-HDHA) may indicate greater capacity for conversion to SPM at times of need, with clear functional implications for populations with low tissue EPA and DHA stores.

The accumulating evidence suggests that tissue LC *n*-3 PUFA are crucial in moderating inflammatory responses in the cardiovascular system. Consequently individuals with no dietary intake of marine *n*-3 PUFA may be at risk

Fig. 2. Overview of the hypothesised role of membrane PUFA profiles in the production of pro-inflammatory and inflammation-resolving oxygenated lipid mediators. In addition to inhibition of arachidonic acid (ARA)-derived pro-inflammatory eicosanoid production, higher proportions of membrane phospholipid long chain (LC) *n*-3 PUFA may increase availability of LC *n*-3 PUFA available for enzymic oxygenation to lipid mediators that contribute to the resolution of an acute inflammatory response⁽⁹⁰⁾. ALA, α -linolenic acid; COX, cyclooxygenase; CYP450, cytochrome P450; HDHA, hydroxyl-DHA; HEPE, hydroxyeicosapentaenoic acid; LA, linoleic acid; LOX, lipoxygenase; PLA₂, phospholipase A₂; SPM, specialised pro-resolving mediators.

of incurring inflammatory-related neuronal and cardiovascular damage at a greater rate than fish-consumers. An adverse LC *n*-3 PUFA-derived lipid mediator profile may also be implicated in impaired haemostatic function in vegetarians⁽¹⁰²⁾. However, presently these ideas remain strictly hypothetical. Health-conscious non-fish-consuming populations may also have a greater bioavailability of ALA- and linoleic acid (LA; 18:2*n*-6)-derived lipid mediators that may have cytoprotective effects^(103,104), although this may not be applicable to the majority of the non-fish-eating population. Few of these lipid mediators have been fully characterised regarding their functional effects, but evidence in animal and cell models to date suggests that plant PUFA-derived oxygenated lipid mediators comprise a complex array of diverse bioactive molecules that may also induce a range of physiological effects in various tissues^(105–107).

Alternative sources for non-fish consumers?

Soya and rapeseed oils are particularly rich in ALA, with the main dietary sources of ALA being cereal-based

products, cooking oils and spreading fats, and vegetables. The high concentrations in oilseed crops presents a potentially easy, sustainable and cheap alternative source of *n*-3 PUFA, but the evidence for a protective effect against CVD is weaker in comparison with marine *n*-3 fatty acids⁽¹⁰⁸⁾. Populations in Europe and the USA consume 3–9 % of energy as LA^(16,109). Dietary intake of ALA has proven difficult to assess due to methodological limitations associated with accurate fatty acid composition data in food databases, but intakes are estimated to be much lower (0.3–0.8 % energy)^(16,109) than LA intakes, which would limit the amount of endogenous LC *n*-3 PUFA production from ALA⁽⁵⁷⁾. Reports are conflicting as to whether vegans/vegetarians consume more ALA than omnivores/fish-eaters^(49,50,110). Dietary LA intakes on the other hand tend to be higher in vegetarians/vegans than omnivores^(49,50), which may also limit conversion of ALA to EPA through substrate competition⁽¹¹¹⁾. Furthermore, supplementation with additional ALA in vegans appears to be ineffective in increasing conversion to LC *n*-3 PUFA⁽¹¹²⁾ and supplementation with pre-formed EPA and DHA may be

necessary for cardioprotective benefit in non-fish-eating populations.

GM crops that can yield EPA and DHA are well-advanced along the experimental process⁽¹¹³⁾, although the first human trial using LC *n*-3 PUFA-rich *Camelina sativa* oil has only just commenced at the time of writing. The main impetus for this bioengineering research was to find a way of producing EPA- and DHA-rich oil to replace fish oils to feed farmed fish⁽¹¹⁴⁾, but the development of transgenic oilseed crops, using genes from microalgae to synthesise EPA and DHA from shorter chain PUFA, could provide an alternative to fish oil for human supplementation and food fortification. The other, already commercially available, option is DHA-only and DHA + EPA-rich microalgal oil⁽¹¹⁵⁾. These LC *n*-3 PUFA rich algal oils have been demonstrated to increase the DHA content of phospholipids efficiently and to have TAG- and blood pressure-lowering properties^(116–120). Microalgal oils are also already being used to supplement infant formula and a limited range of adult foods but the limited scale of production and high costs presently precludes any efforts to apply to large populations⁽¹²¹⁾. Furthermore, little is known about what dosage and which EPA : DHA ratio is likely to be cardio-protective in disease-free populations with low ω -3 indices⁽¹²²⁾. High-DHA purified fish oils are slightly more effective than high-EPA equivalents in lowering blood pressure⁽¹²³⁾. DHA-only algal oil consumed in combination with a fatty meal appears to avoid the less desirable effects of increasing postprandial concentrations of plasma F₂ isoprostanes (markers of oxidative stress produced from arachidonic acid following non-enzymatic reaction with reactive oxygen species) compared with EPA + DHA containing fish oil⁽¹²⁴⁾. However, although retroconversion of DHA to EPA is estimated at between 8 and 14 %⁽¹²⁵⁾, the functional consequences of the lack of dietary EPA against the background of plentiful dietary DHA are not known and may be significant if EPA-derived lipid mediators have any tissue specific roles in cytoprotection. It is equally possible that EPA supplementation is less effective and that DHA-only oils are sufficient to reduce risk of lethal arrhythmia. On the whole, fish oil supplementation studies to date have not considered baseline ω -3 status, which in hindsight has hindered progress towards a robust body of evidence that can be used to formulate dietary guidelines⁽²⁶⁾ and consequently necessitates a fresh approach to gathering new evidence on whether non-fish-consuming populations would be at reduced risk of CHD if they had access to alternative dietary sources of EPA and DHA.

Conclusion

Observational evidence suggests that non-fish-consumers may be at greater risk of CHD mortality and low EPA + DHA tissue status is associated with increased risk of cardiac events, with arrhythmia being implicated as the most likely common risk factor. Preliminary evidence presented here suggests that vegans, who have an ω -3 index of approximately 2–3 %, may have an impaired

capacity to regulate HR in response to physiological demands during the day-time, and they have a distinct lipidomic profile compared with omnivores, with markedly lower circulating concentrations of LC *n*-3 PUFA-derived lipid mediators. However, there is a large gap in the literature regarding the effects of EPA and DHA supplementation in populations characterised by having a low ω -3 index and the relative roles of EPA and DHA remain to be determined before supplementation can be recommended. The question of determining the safest and most effective EPA : DHA ratio for optimum cardio-protection when delivering these fatty acids outside the matrix of the whole seafood seems to be imperative in the context of the small proportion of the population who are actually meeting the fish intake guidelines. Moreover, this question is even more important when considering the increasingly pressing challenges of sustainability of wild fish stocks, and the huge estimated shortfall in total EPA + DHA presently available for human consumption if global human dietary requirements are to be met⁽¹²⁶⁾.

Acknowledgements

The author is grateful to Ana-Margarida Pinto, Tom Sanders, Ana Nicolaou, Alexandra Kendall and Caroline Wheeler-Jones for collaborations and discussions that inspired the content of this review and to Sarah Berry for critical review of the initial manuscript draft.

Financial Support

None.

Conflicts of Interest

None.

Authorship

W. H. wrote the manuscript.

References

1. Burdge GC (2006) Metabolism of alpha-linolenic acid in humans. *Prostaglandins Leukot Essent Fatty Acids* **75**, 161–168.
2. Bradbury J (2011) Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain. *Nutrients* **3**, 529–554.
3. Chamberlain JG (1996) The possible role of long-chain, omega-3 fatty acids in human brain phylogeny. *Perspect Biol Med* **39**, 436–445.
4. Broadhurst CL, Cunnane SC & Crawford MA (1998) Rift Valley lake fish and shellfish provided brain-specific nutrition for early Homo. *Br J Nutr* **79**, 3–21.

5. Crawford MA, Bloom M, Broadhurst CL *et al.* (1999) Evidence for the unique function of docosahexaenoic acid during the evolution of the modern hominid brain. *Lipids* **34**, S39–S47.
6. Michael-Titus AT & Priestley JV (2014) Omega-3 fatty acids and traumatic neurological injury: from neuroprotection to neuroplasticity? *Trends Neurosci* **37**, 30–38.
7. Janssen CI & Kiliaan AJ (2014) Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. *Prog Lipid Res* **53**, 1–17.
8. Makrides M, Smithers LG & Gibson RA (2010) Role of long-chain polyunsaturated fatty acids in neurodevelopment and growth. *Nestle Nutr Workshop Ser Pediatr Program* **65**, 123–133; discussion 133–126.
9. Dyall SC (2015) Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. *Front Aging Neurosci* **7**, 52.
10. Robson LG, Dyall S, Sidloff D *et al.* (2010) Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. *Neurobiol Aging* **31**, 678–687.
11. Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. *Biochim Biophys Acta* **1851**, 469–484.
12. Bazan NG, Molina MF & Gordon WC (2011) Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. *Annu Rev Nutr* **31**, 321–351.
13. Zheng J, Huang T, Yu Y *et al.* (2012) Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. *Public Health Nutr* **15**, 725–737.
14. Albert CM, Campos H, Stampfer MJ *et al.* (2002) Blood levels of long-chain *n*-3 fatty acids and the risk of sudden death. *N Engl J Med* **346**, 1113–1118.
15. Marchioli R, Barzi F, Bomba E *et al.* (2002) Early protection against sudden death by *n*-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation* **105**, 1897–1903.
16. EFSA Panel on Dietetic Products N, and Allergies (NDA) (2010) Scientific opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. *EFSA J* **8**, 107.
17. Sinclair HM (1953) The diet of Canadian Indians and Eskimos. *Proc Nutr Soc* **12**, 69–82.
18. Dyerberg J & Bang HO (1979) Lipid metabolism, atherogenesis, and haemostasis in Eskimos: the role of the prostaglandin *n*-3 family. *Haemostasis* **8**, 227–233.
19. Bang HO, Dyerberg J & Nielsen AB (1971) Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. *Lancet* **1**, 1143–1145.
20. Mozaffarian D & Wu JH (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. *J Am Coll Cardiol* **58**, 2047–2067.
21. Chowdhury R, Warnakula S, Kunutsor S *et al.* (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. *Ann Intern Med* **160**, 398–406.
22. Rizos EC, Ntzani EE, Bika E *et al.* (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *JAMA* **308**, 1024–1033.
23. Burr ML, Fehily AM, Gilbert JF *et al.* (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). *Lancet* **2**, 757–761.
24. Tavazzi L, Maggioni AP, Marchioli R *et al.* (2008) Effect of *n*-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* **372**, 1223–1230.
25. von Schacky C (2014) Omega-3 index and cardiovascular health. *Nutrients* **6**, 799–814.
26. Dwyer JT, Rubin KH, Fritsche KL *et al.* (2016) Creating the future of evidence-based nutrition recommendations: case studies from lipid research. *Adv Nutr* **7**, 747–755.
27. Wu JH & Mozaffarian D (2014) ω -3 fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle. *Heart* **100**, 530–533.
28. Rice HB, Bernasconi A, Maki KC *et al.* (2016) Conducting omega-3 clinical trials with cardiovascular outcomes: proceedings of a workshop held at ISSFAL 2014. *Prostaglandins Leukot Essent Fatty Acids* **107**, 30–42.
29. Smith CE, Follis JL, Nettleton JA *et al.* (2015) Dietary fatty acids modulate associations between genetic variants and circulating fatty acids in plasma and erythrocyte membranes: meta-analysis of nine studies in the CHARGE consortium. *Mol Nutr Food Res* **59**, 1373–1383.
30. Al-Hilal M, AlSaleh A, Maniou Z *et al.* (2013) Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement. *J Lipid Res* **54**, 542–551.
31. AlSaleh A, Maniou Z, Lewis FJ *et al.* (2014) ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement. *Genes Nutr* **9**, 362.
32. Grenon SM, Conte MS, Nosova E *et al.* (2013) Association between *n*-3 polyunsaturated fatty acid content of red blood cells and inflammatory biomarkers in patients with peripheral artery disease. *J Vasc Surg* **58**, 1283–1290.
33. Harris WS, Sands SA, Windsor SL *et al.* (2004) Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. *Circulation* **110**, 1645–1649.
34. Harris WS & Von Schacky C (2004) The Omega-3 Index: a new risk factor for death from coronary heart disease? *Prev Med* **39**, 212–220.
35. Kleber ME, Delgado GE, Lorkowski S *et al.* (2016) Omega-3 fatty acids and mortality in patients referred for coronary angiography. The Ludwigshafen Risk and Cardiovascular Health Study. *Atherosclerosis* **252**, 175–181.
36. Browning LM, Walker CG, Mander AP *et al.* (2012) Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. *Am J Clin Nutr* **96**, 748–758.
37. Walker CG, Browning LM, Mander AP *et al.* (2014) Age and sex differences in the incorporation of EPA and DHA into plasma fractions, cells and adipose tissue in humans. *British J Nutr* **111**, 679–689.
38. Cao J, Schwichtenberg KA, Hanson NQ *et al.* (2006) Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. *Clin Chem* **52**, 2265–2272.
39. Dunstan JA, Mori TA, Barden A *et al.* (2004) Effects of *n*-3 polyunsaturated fatty acid supplementation in pregnancy on maternal and fetal erythrocyte fatty acid composition. *Eur J Clin Nutr* **58**, 429–437.
40. Siscovick DS, Raghunathan TE, King I *et al.* (1995) Dietary intake and cell membrane levels of long-chain *n*-3

- polyunsaturated fatty acids and the risk of primary cardiac arrest. *JAMA* **274**, 1363–1367.
41. Block RC, Harris WS, Reid KJ *et al.* (2008) EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. *Atherosclerosis* **197**, 821–828.
 42. Key TJ, Fraser GE, Thorogood M *et al.* (1999) Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies. *Am J Clin Nutr* **70**, 516S–524S.
 43. Huang T, Yang B, Zheng J *et al.* (2012) Cardiovascular disease mortality and cancer incidence in vegetarians: a meta-analysis and systematic review. *Ann Nutr Metab* **60**, 233–240.
 44. Kwok CS, Umar S, Myint PK *et al.* (2014) Vegetarian diet, Seventh Day Adventists and risk of cardiovascular mortality: a systematic review and meta-analysis. *Int J Cardiol* **176**, 680–686.
 45. Key TJ, Appleby PN & Rosell MS (2006) Health effects of vegetarian and vegan diets. *Proc Nutr Soc* **65**, 35–41.
 46. Bradbury KE, Crowe FL, Appleby PN *et al.* (2015) Serum concentrations of cholesterol, apolipoprotein A-I and apolipoprotein B in a total of 1694 meat-eaters, fish-eaters, vegetarians and vegans. *Eur J Clin Nutr* **69**, 1180.
 47. Appleby PN, Davey GK & Key TJ (2002) Hypertension and blood pressure among meat eaters, fish eaters, vegetarians and vegans in EPIC-Oxford. *Public Health Nutr* **5**, 645–654.
 48. Sanders TA (2014) Plant compared with marine *n*-3 fatty acid effects on cardiovascular risk factors and outcomes: what is the verdict? *Am J Clin Nutr* **100**, Suppl. 1, 453S–458S.
 49. Sanders TA (2009) DHA status of vegetarians. *Prostaglandins Leukot Essent Fatty Acids* **81**, 137–141.
 50. Welch AA, Shakyia-Shrestha S, Lentjes MA *et al.* (2010) Dietary intake and status of *n*-3 polyunsaturated fatty acids in a population of fish-eating and non-fish-eating meat-eaters, vegetarians, and vegans and the product-precursor ratio [corrected] of alpha-linolenic acid to long-chain *n*-3 polyunsaturated fatty acids: results from the EPIC-Norfolk cohort. *Am J Clin Nutr* **92**, 1040–1051.
 51. Snowdon DA (1988) Animal product consumption and mortality because of all causes combined, coronary heart disease, stroke, diabetes, and cancer in Seventh-day Adventists. *Am J Clin Nutr* **48**, 739–748.
 52. Beeson WL, Mills PK, Phillips RL *et al.* (1989) Chronic disease among Seventh-day Adventists, a low-risk group. Rationale, methodology, and description of the population. *Cancer* **64**, 570–581.
 53. Berkel J & de Waard F (1983) Mortality pattern and life expectancy of Seventh-Day Adventists in the Netherlands. *Int J Epidemiol* **12**, 455–459.
 54. Orlich MJ, Singh PN, Sabaté J *et al.* (2013) Vegetarian dietary patterns and mortality in Adventist Health Study 2. *JAMA Intern Med* **173**, 1230–1238.
 55. Appleby PN, Crowe FL, Bradbury KE *et al.* (2016) Mortality in vegetarians and comparable nonvegetarians in the United Kingdom. *Am J Clin Nutr* **103**, 218–230.
 56. Crowe FL, Appleby PN, Travis RC *et al.* (2013) Risk of hospitalization or death from ischemic heart disease among British vegetarians and nonvegetarians: results from the EPIC-Oxford cohort study. *Am J Clin Nutr* **97**, 597–603.
 57. Rosell MS, Lloyd-Wright Z, Appleby PN *et al.* (2005) Long-chain *n*-3 polyunsaturated fatty acids in plasma in British meat-eating, vegetarian, and vegan men. *Am J Clin Nutr* **82**, 327–334.
 58. Key TJ, Appleby PN, Spencer EA *et al.* (2009) Mortality in British vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford). *Am J Clin Nutr* **89**, 1613S–1619S.
 59. Schöttker B, Jorde R, Peasey A *et al.* (2014) Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. *BMJ* **348**, g3656.
 60. Vaishnav S, Stevenson R, Marchant B *et al.* (1994) Relation between heart rate variability early after acute myocardial infarction and long-term mortality. *Am J Cardiol* **73**, 653–657.
 61. Quintana M, Storck N, Lindblad LE *et al.* (1997) Heart rate variability as a means of assessing prognosis after acute myocardial infarction. A 3-year follow-up study. *Eur Heart J* **18**, 789–797.
 62. (1996) Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Eur Heart J* **17**, 354–381.
 63. Tsuji H, Larson MG, Venditti FJ Jr *et al.* (1996) Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. *Circulation* **94**, 2850–2855.
 64. Algra A, Tijssen JG, Roelandt JR *et al.* (1993) Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. *Circulation* **88**, 180–185.
 65. Christensen JH (2011) Omega-3 polyunsaturated Fatty acids and heart rate variability. *Front Physiol* **2**, 84.
 66. Mozaffarian D, Stein PK, Prineas RJ *et al.* (2008) Dietary fish and omega-3 fatty acid consumption and heart rate variability in US adults. *Circulation* **117**, 1130–1137.
 67. Geelen A, Zock PL, Swenne CA *et al.* (2003) Effect of *n*-3 fatty acids on heart rate variability and baroreflex sensitivity in middle-aged subjects. *Am Heart J* **146**, E4.
 68. Dyerberg J, Eskesen DC, Andersen PW *et al.* (2004) Effects of trans- and *n*-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study. *Eur J Clin Nutr* **58**, 1062–1070.
 69. Christensen JH, Christensen MS, Dyerberg J *et al.* (1999) Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with *n*-3 fatty acids. *Am J Clin Nutr* **70**, 331–337.
 70. Svensson M, Schmidt EB, Jorgensen KA *et al.* (2007) The effect of *n*-3 fatty acids on heart rate variability in patients treated with chronic hemodialysis. *J Ren Nutr* **17**, 243–249.
 71. Christensen JH, Korup E, Aaroe J *et al.* (1997) Fish consumption, *n*-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. *Am J Cardiol* **79**, 1670–1673.
 72. O'Keefe JH Jr, Abuissa H, Sastre A *et al.* (2006) Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. *Am J Cardiol* **97**, 1127–1130.
 73. Christensen JH, Gustenhoff P, Korup E *et al.* (1996) Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. *BMJ* **312**, 677–678.
 74. Hamaad A, Kaeng Lee W, Lip GYH *et al.* (2006) Oral omega *n*-3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients. *Cardiovasc Drugs Ther* **20**, 359–364.
 75. DeGiorgio CM, Miller P, Meymandi S *et al.* (2008) *n*-3 fatty acids (fish oil) for epilepsy, cardiac risk factors, and risk of SUDEP: clues from a pilot, double-blind, exploratory study. *Epilepsy Behav* **13**, 681–684.
 76. Xin W, Wei W & Li XY (2013) Short-term effects of fish-oil supplementation on heart rate variability in

- humans: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* **97**, 926–935.
77. Verkerk AO, den Ruijter HM, Bourrier J *et al.* (2009) Dietary fish oil reduces pacemaker current and heart rate in rabbit. *Heart Rhythm* **6**, 1485–1492.
 78. Billman GE (2013) The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: a critical reassessment. *Pharmacol Ther* **140**, 53–80.
 79. Mozaffarian D, Geelen A, Brouwer IA *et al.* (2005) Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. *Circulation* **112**, 1945–1952.
 80. Pinto AM, Sanders TAB, Kendall AC *et al.* (2017) A comparison of heart rate variability, *n*-3 PUFA status and lipid mediator profile in age- and BMI-matched middle-aged vegans and omnivores. *British J Nutr* **117**, 669–685.
 81. Thies F, Garry JM, Yaqoob P *et al.* (2003) Association of *n*-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. *Lancet* **361**, 477–485.
 82. Dyall SC & Michael-Titus AT (2008) Neurological benefits of omega-3 fatty acids. *Neuromol Med* **10**, 219–235.
 83. Papaioannou VE, Verkerk AO, Amin AS *et al.* (2013) Intracardiac origin of heart rate variability, pacemaker funny current and their possible association with critical illness. *Curr Cardiol Rev* **9**, 82–96.
 84. Lanza GA, Sgueglia GA, Cianflone D *et al.* (2006) Relation of heart rate variability to serum levels of C-reactive protein in patients with unstable angina pectoris. *Am J Cardiol* **97**, 1702–1706.
 85. Malave HA, Taylor AA, Nattama J *et al.* (2003) Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure. *Chest* **123**, 716–724.
 86. Farzaneh-Far R, Harris WS, Garg S *et al.* (2009) Inverse association of erythrocyte *n*-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: the Heart and Soul Study. *Atherosclerosis* **205**, 538–543.
 87. Ferrucci L, Cherubini A, Bandinelli S *et al.* (2006) Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. *J Clin Endocrinol Metab* **91**, 439–446.
 88. Fontes JD, Rahman F, Lacey S *et al.* (2015) Red blood cell fatty acids and biomarkers of inflammation: a cross-sectional study in a community-based cohort. *Atherosclerosis* **240**, 431–436.
 89. Skulas-Ray AC (2015) Omega-3 fatty acids and inflammation: a perspective on the challenges of evaluating efficacy in clinical research. *Prostaglandins Other Lipid Mediat* **116–117**, 104–111.
 90. Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. *Nature* **510**, 92–101.
 91. Bazan NG, Musto AE & Knott EJ (2011) Endogenous signaling by omega-3 docosahexaenoic acid-derived mediators sustains homeostatic synaptic and circuitry integrity. *Mol Neurobiol* **44**, 216–222.
 92. Galano JM, Lee JC, Gladine C *et al.* (2015) Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and α -linolenic acids; bioactivities and potential use as biomarkers. *Biochim Biophys Acta* **1851**, 446–455.
 93. Gladine C, Newman JW, Durand T *et al.* (2014) Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention. *PLoS ONE* **9**, e89393.
 94. Gladine C, Laurie JC, Giulia C *et al.* (2014) Neuroprostanes, produced by free-radical mediated peroxidation of DHA, inhibit the inflammatory response of human macrophages. *Free Radic Biol Med* **75**, Suppl. 1, S15.
 95. Roy J, Oger C, Thireau J *et al.* (2015) Nonenzymatic lipid mediators, neuroprostanes, exert the antiarrhythmic properties of docosahexaenoic acid. *Free Radic Biol Med* **86**, 269–278.
 96. Wang X, Hjorth E, Vedin I *et al.* (2015) Effects of *n*-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. *J Lipid Res* **56**, 674–681.
 97. Mas E, Croft KD, Zahra P *et al.* (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following *n*-3 fatty acid supplementation. *Clin Chem* **58**, 1476–1484.
 98. Barden AE, Mas E, Croft KD *et al.* (2015) Specialized proresolving lipid mediators in humans with the metabolic syndrome after *n*-3 fatty acids and aspirin. *Am J Clin Nutr* **102**, 1357–1364.
 99. Barden A, Mas E, Croft KD *et al.* (2014) Short-term *n*-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. *J Lipid Res* **55**, 2401–2407.
 100. Mas E, Barden A, Burke V *et al.* (2016) A randomized controlled trial of the effects of *n*-3 fatty acids on resolvins in chronic kidney disease. *Clin Nutr* **35**, 331–336.
 101. Schuchardt JP, Schmidt S, Kressel G *et al.* (2014) Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men. *Prostaglandins Leukot Essent Fatty Acids* **90**, 27–37.
 102. Mezzano D, Muñoz X, Martínez C *et al.* (1999) Vegetarians and cardiovascular risk factors: hemostasis, inflammatory markers and plasma homocysteine. *Thromb Haemost* **81**, 913–917.
 103. Ramsden CE, Ringel A, Feldstein AE *et al.* (2012) Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. *Prostaglandins Leukot Essent Fatty Acids* **87**, 135–141.
 104. Kumar N, Gupta G, Anilkumar K *et al.* (2016) 15-Lipoxygenase metabolites of α -linolenic acid, [13-(S)-HPOTrE and 13-(S)-HOTrE], mediate anti-inflammatory effects by inactivating NLRP3 inflammation. *Sci Rep* **6**, 31649.
 105. Choque B, Catheline D, Rioux V *et al.* (2014) Linoleic acid: between doubts and certainties. *Biochimie* **96**, 14–21.
 106. Harizi H, Corcuff JB & Gualde N (2008) Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. *Trends Mol Med* **14**, 461–469.
 107. Nicolaou A, Mauro C, Urquhart P *et al.* (2014) Polyunsaturated fatty acid-derived lipid mediators and T cell function. *Front Immunol* **5**, 75.
 108. Fleming JA & Kris-Etherton PM (2014) The evidence for α -linolenic acid and cardiovascular disease benefits: comparisons with eicosapentaenoic acid and docosahexaenoic acid. *Adv Nutr* **5**, 863S–876S.
 109. US Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center, Food Surveys Research Group and US 1002 Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (2013) *What We Eat in America*. NHANES 2009–2010 Data: Dietary Interview - Total Nutrients Intakes, First Day (DR1TOT_F). Available from <https://www.nchhs.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2009> (accessed April 2017).

110. Kornsteiner M, Singer I & Elmadfa I (2008) Very low *n*-3 long-chain polyunsaturated fatty acid status in Austrian vegetarians and vegans. *Ann Nutr Metab* **52**, 37–47.
111. Liou YA, King DJ, Zibrik D *et al.* (2007) Decreasing Linoleic Acid with Constant α -Linolenic Acid in Dietary Fats Increases (*n*-3) Eicosapentaenoic Acid in Plasma Phospholipids in Healthy Men. *J Nutr* **137**, 945–952.
112. Fokkema MR, Brouwer DA, Hasperhoven MB *et al.* (2000) Short-term supplementation of low-dose gamma-linolenic acid (GLA), alpha-linolenic acid (ALA), or GLA plus ALA does not augment LCP omega 3 status of Dutch vegans to an appreciable extent. *Prostaglandins Leukot Essent Fatty Acids* **63**, 287–292.
113. Napier JA, Usher S, Haslam RP *et al.* (2015) Transgenic plants as a sustainable, terrestrial source of fish oils. *Eur J Lipid Sci Technol* **117**, 1317–1324.
114. Betancor MB, Sprague M, Usher S *et al.* (2015) A nutritionally-enhanced oil from transgenic *Camelina sativa* effectively replaces fish oil as a source of eicosapentaenoic acid for fish. *Sci Rep* **5**, 8104.
115. Sarter B, Kelsey KS, Schwartz TA *et al.* (2015) Blood docosahexaenoic acid and eicosapentaenoic acid in vegans: associations with age and gender and effects of an algal-derived omega-3 fatty acid supplement. *Clin Nutr* **34**, 212–218.
116. Maki KC, Yurko-Mauro K, Dicklin MR *et al.* A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia. *Prostaglandins, Leukot Essent Fatty Acids* **91**, 141–148.
117. Conquer JA & Holub BJ (1996) Supplementation with an algae source of docosahexaenoic acid increases (*n*-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. *J Nutr* **126**, 3032–3039.
118. Geppert J, Kraft V, Demmelmair H *et al.* (2005) Docosahexaenoic acid supplementation in vegetarians effectively increases omega-3 index: a randomized trial. *Lipids* **40**, 807–814.
119. Bernstein AM, Ding EL, Willett WC *et al.* (2012) A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. *J Nutr* **142**, 99–104.
120. Theobald HE, Goodall AH, Sattar N *et al.* (2007) Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. *J Nutr* **137**, 973–978.
121. Chauton MS, Reitan KI, Norsker NH *et al.* (2015) A techno-economic analysis of industrial production of marine microalgae as a source of EPA and DHA-rich raw material for aquafeed: research challenges and possibilities. *Aquaculture* **436**, 95–103.
122. Cottin SC, Sanders TA & Hall WL (2011) The differential effects of EPA and DHA on cardiovascular risk factors. *Proc Nutr Soc* **70**, 215–231.
123. Mori TA, Bao DQ, Burke V *et al.* (1999) Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. *Hypertension* **34**, 253–260.
124. Purcell R, Latham SH, Botham KM *et al.* (2014) High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F-2 alpha concentrations relative to a control high-oleic acid meal: a randomized controlled trial. *Am J Clin Nutr* **100**, 1019–1028.
125. Conquer JA & Holub BJ (1997) Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. *Lipids* **32**, 341–345.
126. Salem N & Eggersdorfer M (2015) Is the world supply of omega-3 fatty acids adequate for optimal human nutrition? *Curr Opin Clin Nutr Metab Care* **18**, 147–154.
127. Cottin SC, Alsaleh A, Sanders TAB *et al.* (2016) Lack of effect of supplementation with EPA or DHA on platelet-monocyte aggregates and vascular function in healthy men. *Nutr Metab Cardiovasc* **26**, 743–751.
128. Johnston DT, Deuster PA, Harris WS *et al.* (2013) Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed U.S. Servicemembers. *Nutr Neurosci* **16**, 30–38.
129. Reidlinger DP, Darzi J, Hall WL *et al.* (2015) How effective are current dietary guidelines for cardiovascular disease prevention in healthy middle-aged and older men and women? A randomized controlled trial. *Am J Clin Nutr* **101**, 922–930.
130. Sanders TA, Lewis F, Slaughter S *et al.* (2006) Effect of varying the ratio of *n*-6 to *n*-3 fatty acids by increasing the dietary intake of alpha-linolenic acid, eicosapentaenoic and docosahexaenoic acid, or both on fibrinogen and clotting factors VII and XII in persons aged 45–70 y: the OPTILIP study. *Am J Clin Nutr* **84**, 513–522.
131. Sanders TA, Gleason K, Griffin B *et al.* (2006) Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6*n*-3) and docosapentaenoic acid (22:5*n*-6) on cardiovascular risk factors in healthy men and women. *Br J Nutr* **95**, 525–531.
132. Agren JJ, Törmälä ML, Nenonen MT *et al.* (1995) Fatty acid composition of erythrocyte, platelet, and serum lipids in strict vegans. *Lipids* **30**, 365–369.
133. Fokkema MR, Brouwer DA, Hasperhoven MB *et al.* (2000) Polyunsaturated fatty acid status of Dutch vegans and omnivores. *Prostaglandins Leukot Essent Fatty Acids* **63**, 279–285.
134. Rajaram S, Haddad EH, Mejia A *et al.* (2009) Walnuts and fatty fish influence different serum lipid fractions in normal to mildly hyperlipidemic individuals: a randomized controlled study. *Am J Clin Nutr* **89**, 1657S–1663S.
135. Sanders TA, Ellis FR & Dickerson JW (1978) Studies of vegans: the fatty acid composition of plasma choline phosphoglycerides, erythrocytes, adipose tissue, and breast milk, and some indicators of susceptibility to ischemic heart disease in vegans and omnivore controls. *Am J Clin Nutr* **31**, 805–813.
136. Blausen Gallery (2014) *Wikiversity J Med*. Available from https://en.wikiversity.org/wiki/File:Blausen_0259_CoronaryArteryDisease_02.png (accessed April 2017).